Parasites, Hosts and Diseases
- Volume 30 Issue 2
- /
- Pages.133-140
- /
- 1992
- /
- 2982-5164(pISSN)
- /
- 1738-0006(eISSN)
Immunogenicity and Protective Efficacy of Solubilized Merozoite-enriched Theileria sergenti Immunogens I: Protection against Homologous Stabilate Challenge
Theileriu sergenti merozoite 수용성 항원의 항원성과 면역성
Abstract
Theileria sergenti were isolated from infected erythrocytes by hypotonic Iysis, and soluble meroBoite antigens were purified by sonication and differential centrifugation. The preparation contained 29, 34, 35 and 105 kD immuno-dominant polypeptides. The soluble antigens (0.5 mg/ml) were prepared and fortified with Freund's adjuvant. Five month old naive Korean calves were subcutaneously inoculated with the preparation and a booster dose was administered 4 weeks later Nine weeks after the booster dose, vaccinates and controls were challenged with a homologous stabilate (5.6×106 RBC/dose, 40% Parasitemia). All animals were monitored for hematocrit, total erythrocyte count, parasitemia and for the specific antibody by Western immuno- blot (WB) and indirect immuno-auorescent antibody(IFA) test. By 18 weeks after vaccination (6 weeks after the challenge), vaccinated cattle had an average IFA titer of 1 : 10,240 compared with 1 : 1,280 of the controls. The vaccinates showed ne91igib1e change in hematocrit and total RBC count whereas control animals showed significant (P<0.05) hematological chanties and associated anemia. After vaccination and challenge, the antibody responses demonstrated that vaccination had induced significant production of antibody to the 29 and 35 kD polypeptides. The latter polypeptide was much more strongly recognized by the vaccinated animals, and thus it may be a potential candidate for the vaccine.
T. sergenti merozoite 수용성 항원을 T. sergenti 감염적혈구로부터 분리하고자 저삼투압액으로 용혈, 조직 분쇄기로 분쇄한 후에 고속 원심분리하여 수용성 항원을 얻었으며, SDS-PAGE와 Western blot의 방법으로 29, 34, 35 그리고 105 kD가 함유된 항원을 본 예방접종실험의 항원성 polypeptide로 정하였다. 본 수용성 항원(0.5 mg/ml)을 준비, Freund's adjunant를 이용하여 한우(5개월령)에 경피 접종하였으며, 다시 4주 후에 추가접종하였다. 추가접종 9주 후에 예방 접종군과 대조군에 동종의 냉동충주(5.6